EGFR and non-small cell lung carcinoma: Thus, ongoing efforts are focused on developing enhanced EGFR-TKIs that maintain effectiveness against EGFR-activating mutations while mitigating acquired resistance [15], resulting in the emergence of second- and third-generation EGFR-TKIs for NSCLC treatment [16,17,18,19].